Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Clin Pharmacol Ther. 2017 Nov 28;103(1):112–119. doi: 10.1002/cpt.930

Table 1.

Buprenorphine clinical experience in NAS

Study Publication Design Buprenorphine Comparator (N) Reduction in length
of treatment
(days buprenorphine
vs. comparator)
N Initial dose
(µg/kg/day)		 Maximum dose
(µg/kg/day)
Kraft39 2008 Open label, randomized 13 13.2 39 Morphine (13) 32% (22 vs. 32)
Kraft40 2011 Open label, randomized 12 15.3 60 Morphine (12) 39% (23 vs. 38)
Hall42 2016 Retrospective cohort 38 13.2 39 Methadone (163) 33% (9.3 vs. 14)
Hall43 2017 Retrospective cohort 174 13.5 22.5 Methadone or Morphine (186) 29% (7.4 vs. 10.4)
Kraft41 2017 Blinded, randomized 30 15.3 60 Morphine (33) 46% (15 vs. 28)
MOP Plus (NCT01671410) Unpublished Open label, randomized 6 15.3 60 Morphine (5) N.A.